These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 24714704)

  • 41. New insights into targeting hepatic cystogenesis in autosomal dominant polycystic liver and kidney disease.
    Barten TRM; Bernts LHP; Drenth JPH; Gevers TJG
    Expert Opin Ther Targets; 2020 Jun; 24(6):589-599. PubMed ID: 32250187
    [No Abstract]   [Full Text] [Related]  

  • 42. Polycystic liver and kidney diseases.
    Tahvanainen E; Tahvanainen P; Kääriäinen H; Höckerstedt K
    Ann Med; 2005; 37(8):546-55. PubMed ID: 16338757
    [TBL] [Abstract][Full Text] [Related]  

  • 43. New advances in evaluation and management of patients with polycystic liver disease.
    Arnold HL; Harrison SA
    Am J Gastroenterol; 2005 Nov; 100(11):2569-82. PubMed ID: 16279915
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hepatic venous outflow obstruction in patients with polycystic liver disease: pathogenesis and treatment.
    Uddin W; Ramage JK; Portmann B; Wilson P; Benjamin I; Tan KC; Williams R
    Gut; 1995 Jan; 36(1):142-5. PubMed ID: 7890219
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Screening for cerebral aneurysm in patients with polycystic liver disease.
    Geevarghese SK; Powers T; Marsh JW; Pinson CW
    South Med J; 1999 Dec; 92(12):1167-70. PubMed ID: 10624907
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Therapeutic dilemmas in patients with symptomatic polycystic liver disease.
    Turnage RH; Eckhauser FE; Knol JA; Thompson NW
    Am Surg; 1988 Jun; 54(6):365-72. PubMed ID: 3288024
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Medical therapy for polycystic liver disease.
    Khan S; Dennison A; Garcea G
    Ann R Coll Surg Engl; 2016 Jan; 98(1):18-23. PubMed ID: 26688394
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Autosomal dominant polycystic kidney disease with diffuse proliferative glomerulonephritis - an unusual association: a case report and review of the literature.
    D'Cruz S; Singh R; Mohan H; Kaur R; Minz RW; Kapoor V; Sachdev A
    J Med Case Rep; 2010 Apr; 4():125. PubMed ID: 20429898
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lanreotide Reduces Liver Volume, But Might Not Improve Muscle Wasting or Weight Loss, in Patients With Symptomatic Polycystic Liver Disease.
    Temmerman F; Ho TA; Vanslembrouck R; Coudyzer W; Billen J; Dobbels F; van Pelt J; Bammens B; Pirson Y; Nevens F
    Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2353-9.e1. PubMed ID: 26073493
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-acting somatostatin analogue treatments in autosomal dominant polycystic kidney disease and polycystic liver disease: a systematic review and meta-analysis.
    Griffiths J; Mills MT; Ong AC
    BMJ Open; 2020 Jan; 10(1):e032620. PubMed ID: 31924636
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Germline mutations in PRKCSH are associated with autosomal dominant polycystic liver disease.
    Drenth JP; te Morsche RH; Smink R; Bonifacino JS; Jansen JB
    Nat Genet; 2003 Mar; 33(3):345-7. PubMed ID: 12577059
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Laparoscopic treatment of biliary hepatic cysts: short- and medium-term results.
    Neri V; Ambrosi A; Fersini A; Valentino TP
    HPB (Oxford); 2006; 8(4):306-10. PubMed ID: 18333141
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Scanning electron microscopy of polycystic liver disease.
    Kojima K; Hashimoto M; Ubara Y
    Clin Exp Nephrol; 2018 Oct; 22(5):1226-1227. PubMed ID: 29520518
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Overexpression of Aquaporin 1 on cysts of patients with polycystic liver disease.
    Li D; Shi X; Zhao L; Liang Z; Xie S; Wang G
    Rev Esp Enferm Dig; 2016 Feb; 108(2):71-8. PubMed ID: 26838488
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Neuroendocrine tumor in the liver of a patient with isolated polycystic liver disease: A case report and review of the literature.
    Koutsampasopoulos K; Antoniadou E; Zoutis S; Iacovidis G; Burova O; Taplidis A
    Oncol Lett; 2013 May; 5(5):1664-1666. PubMed ID: 23761831
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Isolated polycystic liver disease.
    Qian Q
    Adv Chronic Kidney Dis; 2010 Mar; 17(2):181-9. PubMed ID: 20219621
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD): Somatostatin analogues and mTOR inhibitors].
    Perico N; Cortinovis M; Remuzzi G
    G Ital Nefrol; 2016; 33(5):. PubMed ID: 27796020
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hepatic cysts treated with percutaneous ethanol sclerotherapy: time to extend the indications to haemorrhagic cysts and polycystic liver disease.
    Benzimra J; Ronot M; Fuks D; Abdel-Rehim M; Sibert A; Farges O; Vilgrain V
    Eur Radiol; 2014 May; 24(5):1030-8. PubMed ID: 24563160
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Complications arising in simple and polycystic liver cysts.
    Macutkiewicz C; Plastow R; Chrispijn M; Filobbos R; Ammori BA; Sherlock DJ; Drenth JP; O'Reilly DA
    World J Hepatol; 2012 Dec; 4(12):406-11. PubMed ID: 23355921
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Excellent survival after liver transplantation for isolated polycystic liver disease: an European Liver Transplant Registry study.
    van Keimpema L; Nevens F; Adam R; Porte RJ; Fikatas P; Becker T; Kirkegaard P; Metselaar HJ; Drenth JP;
    Transpl Int; 2011 Dec; 24(12):1239-45. PubMed ID: 21955068
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.